RESUMO
Background. The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients. Patients and methods. eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed. Results. Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison: "TT" vs "AA" (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed. Conclusion. These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials (AU)
No disponible
Assuntos
Humanos , Masculino , Feminino , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Biomarcadores/metabolismo , Neovascularização Fisiológica/genética , Análise do Polimorfismo de Comprimento de Fragmentos Amplificados/métodos , Preparações Farmacêuticas/administração & dosagem , Terapêutica/métodos , Sobrevivência/psicologia , Ensaios Clínicos como Assunto/métodos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapia , Biomarcadores/análise , Neovascularização Fisiológica/fisiologia , Análise do Polimorfismo de Comprimento de Fragmentos Amplificados/normas , Preparações Farmacêuticas/metabolismo , Terapêutica/instrumentação , Sobrevivência/fisiologia , Ensaios Clínicos como AssuntoRESUMO
BACKGROUND: The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients. PATIENTS AND METHODS: eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed. RESULTS: Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison: "TT" vs "AA" (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed. CONCLUSION: These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials.
Assuntos
Bevacizumab/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Interleucina-8/genética , Óxido Nítrico Sintase Tipo III/genética , Polimorfismo de Nucleotídeo Único , Adulto , Idoso , Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Feminino , Estudos de Associação Genética , Humanos , Pessoa de Meia-Idade , Polimorfismo de Fragmento de Restrição , Prognóstico , Estudos Retrospectivos , Resultado do TratamentoAssuntos
Doenças Profissionais/parasitologia , Dermatopatias Parasitárias , Diagnóstico Diferencial , Humanos , Larva Migrans/diagnóstico , Leishmaniose Cutânea/diagnóstico , Doenças Profissionais/diagnóstico , Dermatopatias Parasitárias/diagnóstico , Dermatopatias Parasitárias/parasitologia , Fatores de TempoRESUMO
The authors describe a case of anisakiasis in Sicily. The diagnosis was based on the knowledge that a contaminated fish, Lepidopus caudatus, had probably been absorbed, as well as on clinical intestinal symptoms, intestinal lesions observed by endoscopy and O.G.D.S, duodenal infiltration by eosinophilic polymorphonuclear, positive ELISA anisakis serology and successful treatment by albendazole.
Assuntos
Anisaquíase/diagnóstico , Animais , Anisaquíase/patologia , Anisaquíase/transmissão , Anisakis/imunologia , Anticorpos Anti-Helmínticos/sangue , Eosinofilia , Peixes/parasitologia , Contaminação de Alimentos , Humanos , Mucosa Intestinal/patologia , Masculino , Pessoa de Meia-IdadeRESUMO
The AA. refer on the first Italian case of amoebae "Limax" primitive myelitis in a 25-year-old man. Microscopical observation showed amoebae free-living, but their cultivation and identification were not possible. The patient recovered because of the propriety of diagnosis and therapy with amphotericin B.
